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ARTICLE IN PRESS

REVIEW ARTICLE
Immune responses to injury and their links to
eye disease
MARY ANN STEPP, and A. SUE MENKO, PHD
WASHINGTON, DC; AND PHILADELPHIA, PENNSYLVANIA

The eye is regarded as an immune privileged site. Since the presence of a vasculature would impair vision, the vasculature of the eye is located outside of the central
light path. As a result, many regions of the eye evolved mechanisms to deliver
immune cells to sites of dysgenesis, injury, or in response to the many age-related
pathologies. While the purpose of these immune responses is reparative or protective, cytokines released by immune cells compromise visual acuity by inducing
inflammation and fibrosis. The response to traumatic or pathological injury is distinct
in different regions of the eye. Age-related diseases impact both the anterior and
posterior segment and lead to reduced quality of life and blindness. Here we focus
attention on the role that inflammation and fibrosis play in the progression of agerelated pathologies of the cornea and the lens as well as in glaucoma, the formation of epiretinal membranes, and in proliferative vitreoretinopathy. (Translational
Research 2021; 000:1 20)
Abbreviations: 2ryERM = epiretinal membrane secondary to disease pathology; ACAID =
anterior chamber immune deviation; APCs = Antigen Presenting Cells, this class includes dendritic cells and monocytes; ASC = anterior subcapsular cataracts; BALB/c = An albino mouse
strain used for research and known to mount a primarily Th2 response to infection; BM = basement membrane; C57BL6 = A pigmented mouse strain used for research and known to mount
a primarily Th1 response to infection; CCL2 = A cytokine expressed early during inflammation
that attracts neutrophils, sometimes referred to as monocyte chemoattractant protein-1
(MCP-1)); CD45 = Cluster of differentiation 45 antigen; CNS = Central Nervous System; CXCL1
= A cytokine expressed early during inflammation that attracts neutrophils; DAMPs = damageassociated molecular patterns; DBA/2J = A strain of pigmented mice used in glaucoma
research; EBM = Epithelial Basement Membrane; ECM = extracellular matrix; EMT = epithelialmesenchymal transition; ERM = epiretinal membrane; F4/80 = A protein encoded by the
ADGRE1 gene that, in mice, is expressed primarily on macrophages; FGF2 = fibroblast growth
factor 2, also referred to as basic FGF; HA =hyaluronic acid; HSK = herpes stromal keratitis; HSP
= heat shock protein; HSPGs = heparan sulfate proteoglycans; HSV = herpes simplex virus; ICN
= intraepithelial corneal nerves; iERM = idiopathic epiretinal membrane; IL-20 = Interleukin-20;
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IL6 = Interleukin 6; ILM = Inner (or internal) limiting membrane; IOP = intraocular pressure;
MAGP1 = Microfibril-associated glycoprotein 1; MHC-II = Major histocompatibility complex
type II, a class of MHC proteins typically found only on APCs; mTOR = mechanistic target of
rapamycin, a protein kinase encoded by the MTOR genes that regulates a variety of signal
transduction events including cell growth, autophagy and actin cytoskeleton; N-cad = Ncadherin; NEI = National Eye Institute; NK = Natural killer T cells; PCO = Posterior capsular opacification; PDGF = Platelet derived growth factor; PDR = proliferative diabetic retinopathy; PVD
= posterior vitreous detachment; PVR = proliferative vitreoretinopathy; Rag1-/- = A mouse
model that lacks functional T and B cells and used to study the immune response; RGC = Retinal ganglion cells; RPE = Retinal pigment epithelial cells; RRD = rhegmatogenous (rupture,
tear) retinal detachment; SMAD = Sons of Mothers Against Decapentaplegic, SMADs are a
class of molecules that mediate TGF and bone morphogenetic protein signaling; TG = trigeminal ganglion; TGF1 = Transforming growth factor 1; Th1 = T-helper cell 1 response, proinflammatory adaptive response involving interferon gamma and associated with autoimmunity; Th17 =
A T-helper cell that expresses high levels of IL-17 which can suppress T-regulatory cell function;
Th2 = T-helper cell 2 response involving IgE and interleukins 4,5, and 13, also induces the antiinflammatory interleukin 10 family cytokines; TM = trabecular meshwork; TNF = Tumor necrosis
factor a cytokine produced during inflammation; Treg = T-regulatory cell; VEGF = Vascular
endothelial growth factor; WHO = World Health Organization; SMA = Smooth muscle actin, a
class of actin expressed in mesenchymal cells

INTRODUCTION

The eye is a unique site whose function relies on the
transparency of several tissues and whose vasculature
is limited to regions outside of the central light path.

Inflammation, such as typically occurs in response to
an injury, be it surgical or pathological, brings with it
the danger of vision impairment (Fig 1). As immune
responses are crucial elements of the repair response,
the eye has developed distinct mechanisms to deliver

Fig 1. Inflammation-induced pathologies in the immune privileged eye. Diagram showing the importance of
immune privilege in the eye to prevent\ocular inflammation and when that privilege is compromised, and innate
immunity activated, inflammation of the eye results in fibrogenic pathologies. Diagram is modified from Murakami et al., Progress in Retinal and Eye Research (2019) 74:100778.232 For interpretation of the references to
color in this figure legend, the reader is referred to the Web version of this article.
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Fig 2. Following corneal debridement wounding immune cells are located along MAGP1-rich fibrils in the cornea stroma at the limbus and corneal periphery. A and D are cartoons showing the anatomical relationships
between the limbus, peripheral cornea, iris, ciliary body and lens. Cryosections obtained from mouse eyes of
unwounded (B,C) or one day post corneal debridement wounding (E, F) were imaged by confocal microscopy at
the limbus (B,E) and the peripheral cornea (C, F). Sections were co-immunolabeled for Microfibril-associated
glycoprotein 1 or MAGP1 (purple), the immune cell marker CD45 (green), and nuclei (blue). MAGP1 associates
with fibrillin in the ciliary zonules. Magnification bars = 20mm. CB= ciliary body, CZ= ciliary zonules. This
figure is adapted from DeDreu et al., FASEB J. (2020) 34:9316.163 For interpretation of the references to color
in this figure legend, the reader is referred to the Web version of this article.

immune responses to injury in avascular regions of the
eye. In this review, we cover the common injuries and
pathologies in these regions of the eye, how the
immune system responds, and the link between inflammation and the negative outcomes of these immune
responses, including fibrosis, that impair vision.

IMMUNE RESPONSES IN CORNEAL KERATITIS
Immune Mediated Wound Healing and Fibrosis: The

The term “ocular
surface” embraces the corneal and conjunctival epithelia and the tear film1-3 as well as a number of other ocular features including the lacrimal and Meibomian
glands and the ocular microbiome. While the term had
not originally included the intraepithelial corneal
nerves (ICNs), the cells in the corneal stroma, or the
corneal endothelial cells, homeostasis of the ocular surface requires contributions from all of these components. Resident and recruited immune cells maintain
cornea and the ocular surface.

the ocular surface.4-7 Recurrent erosions, corneal dystrophies, stem cell deficiency, infection by microorganisms, and autoimmune mediated diseases all disrupt
the cornea and ocular surface and can lead to severe
pathology and blindness. In the cornea, fibrosis presents
as diffuse haze that can be transient or permanent or as
focal opaque scars in the anterior or posterior stroma.8-10
The terms fibrosis and scar are often used interchangeably
in describing pathologies affecting the cornea. A common
feature of corneal fibrosis is the increased expression of
TGBb1 by stromal cells.8,11-13 If in the central cornea,
fibrosis causes an increase in refractive error and/or astigmatism.
The immunology of the cornea has been extensively
studied; yet its complexity has made understanding its
role in homeostasis and disease progression challenging. While considered immune privileged, the cornea
has a robust resident immune cell population that
responds quickly to trauma and/or infection (Fig 2).
The cornea’s immune response is dominated by the
process referred to as Anterior Chamber Immune

ARTICLE IN PRESS
4

Stepp and Menko

Deviation or ACAID.14-16 ACAID was first described
by Streilein and Niederkorn in 1981.17 In the 40 years
since then, ACAID has been shown to play roles in the
induction of peripheral tolerance to eye-derived antigens, allowing corneal transplants to not be rejected.
ACAID allows the anterior segment of the eye to regulate the activation of both innate and adaptive immune
responses. ACAID begins when an antigen is detected
in the anterior chamber. When antigen presenting cells
(APCs) in the iris and ciliary body capture the antigen,
the APCs enter the circulation and travel to either the
thymus or spleen where they induce the generation of
T regulatory cells.18 In his Proctor Lecture for the
Association for Research in Vision and Ophthalmology
in 1996, J. Wayne Streilein referred to ACAID as an
evolutionary “Faustian bargain”.19 ACAID suppresses
the immune response to microorganisms and particulates in the air that get stuck in the tear film and enter
the cornea by eye rubbing and blinking. It also limits
the immune response to ocular tumors and certain
viruses increasing the risk of blindness and death
resulting from these severe, yet far less frequent,
pathologies.19
While ACAID makes the ocular immune response
unique, nonetheless, there are many aspects of the cornea immune response that are shared with the skin and
other mucosal surfaces of the body. Keratitis is the term
used to define the clinical outcome of numerous different corneal pathologies all of which involve inflammation.20 Infectious keratitis is caused by invasion of the
cornea by microorganisms; non-infectious keratitis can
be caused by trauma and/or autoimmune conditions. If
non-infectious keratitis does not resolve, the pathology
can convert into the infectious form. To prevent scarring, keratitis must be treated early and aggressively to
block progression of disease. As the population ages and
the number of people with chronic autoimmune related
conditions increase, the incidence of corneal pathology
due to autoimmunity in the population is increasing. As
the planet warms and temperatures rise, the numbers of
infectious organisms present in the environment and in
our water supply is increasing as well.21 Research is currently being done to refine our understanding of corneal
immunity and inflammation to allow us to develop treatments that halt pathology and permit restoration of function after keratitis resolves.
Non-infectious

forms

pathology. Traumas

of

keratitis

and

corneal

to the cornea are the most common
type of injury to the eye and the most frequent cause for
a patient to be seen by an ophthalmologist in the emergency room setting.22 Our understanding of how the cornea responds to sterile injuries like abrasions is largely
based on the use of rodent models that have examined
the response of the cornea to injury.23-25 Superficial
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injuries to the corneal epithelium typically heal well and
do not lead to scars but they do predispose the cornea to
recurrent epithelial erosions.26 Deeper traumas involving the corneal stroma as well as the corneal epithelium
disrupt the organization of the lamellae of collagen
fibers in the stroma required for corneal transparency.27,28 Restoring tissue integrity requires synthesis
and deposition of extracellular matrix.
Debridement injury activates dendritic cells in the
basal layer of the epithelium and leads to the influx of
neutrophils and platelets into the corneal stroma and of
gd T cells into the corneal epithelium.5,29-33 Dendritic
cells are antigen presenting; after activation they
migrate to the draining lymph nodes and induce the
adaptive immune response. Depleting mice of neutrophils or gd T cells impairs reepithelialization of the
cornea.30,32 Wildtype mice express both IL-20 and its
receptor on corneal epithelial cells, as well as on dendritic cells and monocytes. Treating neutrophil or gd T
cell depleted mice which have delayed wound healing
with IL-20 restores corneal reepithelialization.32 In the
neutrophil depleted mice, IL-20 promoted recruitment
and activation of gd T cells in the wounded cornea. In
gd T cell depleted mice, IL-20 restores corneal reepithelialization without increasing neutrophil influx.
Thus, IL-20 signaling plays an anti-inflammatory role
by limiting neutrophil influx. Yet, in other tissues, IL20 can enhance fibrosis and has been linked to development of autoimmunity.34
Deeper traumas involving both the corneal epithelium and the corneal stroma disrupt the epithelial basement membrane (EBM) and the organization of the
lamellae of collagen fibers in the stroma that generate
corneal transparency.27,28 Once reepithelialization is
complete and the epithelial barrier restored, stromal
immune cells begin removing collagen and elastin
debris from the stroma, as well as the dead immune
cells that were recruited into the stroma during the
acute response to injury.
The EBM is known to play roles in restricting cytokine access to the stroma.10,27,41 Once the EBM is
injured or removed, cytokines from epithelial cells and
tears diffuse into the stroma and activate target cells.
Debridement injuries leave the EBM intact but deeper
wounds do not.42 EBM reassembly begins during reepithelialization but restoring the barrier to cytokines
can take several weeks.25 Stromal repair can also take
weeks or months.41 The de novo synthesis of collagen,
elastin, and proteoglycans in the cornea stroma is mediated by a smooth muscle actin+ (aSMA+) myofibroblasts. Myofibroblasts differentiate from both corneal
stromal keratocytes and fibrocytes during the response
to ocular trauma.43-45 Fibrocytes differentiate from
recruited
monocytes
and/or
resident
tissue
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macrophages. Transforming growth factor b (TGF b) is
a cytokine which functions in both immunity and extracellular matrix regulation.35 TGF b has three isoforms
(TGF b1, TGF b2, and TGF b3) and all three are
expressed by numerous types of immune cells. TGF b1
null mice develop systemic immune cell infiltration
into tissues 36-38 due, in part, to the requirement for
TGF b1 for the formation of T regulatory cells.35 In the
cornea, TGF b1 and TGF b2 are expressed by corneal
epithelial and stromal cells39; they can also be present
in the tears.40 While both isoforms play roles in regulating scar formation after injuries to the stroma, TGF
b1 plays a more important role. While myofibroblast
formation is dependent on TGF b1 signaling, in vitro
studies have shown that TGF b3 reduces the generation
of aSMA+ myofibroblasts and their ability to deposit
collagen into extracellular matrices.46,47 These studies
highlight the complexity involved in TGF b mediated
scar formation in response to deeper keratectomy
wounds.
A single topical application of Mitomycin C at the
time of surgery has been shown to minimize scar formation after refractive and glaucoma surgery.45 The
mechanism underlying MMC-induced reduced cornea
scarring has been shown to be due to reduced conversion of keratocytes to myofibroblasts.44 However,
recent studies have shown that MMC treatment also
alters gene expression in wounded corneal epithelial
cells and enhances reinnervation of the corneal epithelial sensory nerves.26,48 For scars that form secondary to non-surgical trauma, treatments are
limited. One of the most promising treatments is the
use of autologous plasma, rich in growth factors, as
an eye drop.49,50 It is safe, and has been shown to
improve healing by improving keratocyte migration,
reducing TGF b1-induced myofibroblast differentiation, and stimulating scarless regeneration after corneal injury.
Matrix deposition within the stroma after trauma
reestablishes structural integrity but it does so at the
cost of generating haze, caused by disorganization of
the collagen lamellae, and focal scars. Repair mechanisms that evolved to restore corneal strength after
injury often cannot restore the original morphology to
the corneal stroma since collagen fibers often extend
from limbus to limbus across the center of the corneal
stroma.51,52 Studies in the cornea and skin indicate that
delays in apoptosis of the myofibroblasts that appear
during wound-healing is a hallmark of fibrosis.53,54
While the cornea presents challenges to resolving haze
and scars, research on treatments to reduce fibrosis is
one worth investing in going forward. An even slight
decrease in the extent of haze or the size of a centrally
placed corneal scar would make a huge difference to a
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patient’s quality of life and avoid the need for a corneal
transplant.
gd T cells express and secrete the cytokine IL17.55
Another T cell lineage, T-helper (Th17) cells, also
secrete IL17.56 Th17 cells have been studied extensively
with respect to dry eye disease and other autoimmune
conditions impacting the cornea including Sjogren’s
Syndrome.6,57,58 Th17 cells have the ability to suppress
the functions of regulatory T cells (Tregs) .59,60 Loss of
Treg function within tissues and can lead to chronic
inflammation,61,62 whereas excess numbers or activation
of Tregs increases the risk of infection by microorganisms6 and to a wide spectrum of ocular pathologies ranging from dry eye disease and chronic pain to recurrent
erosions. These conditions can lead to cornea scarring
and thinning.63-65 Increased Treg activity increases the
risk of infection by suppressing the activation of cytotoxic T cells.60 Treatments for dry eye disease include
artificial tears, autologous serum eye drops and topical
treatments that suppress the immune response including
cyclosporine A, corticosteroids, tacrolimus, and low
dose tetracycline.66
Infectious keratitis. Infectious keratitis is more likely
to lead to corneal pathology than non-infectious keratitis. The cornea’s immune response to infection is
greater to prevent the CNS (retina and brain) from getting infected. Following diagnosis and identification of
the microorganism involved, drug treatment is initiated. Treatment includes eyedrops and/or direct delivery of drugs by intrastromal or intravitreal
injection.67,68 When fibrosis occurs in the central visual
axis from infectious keratitis it reduces visual acuity; in
severe cases a corneal transplant is recommended. The
microorganisms that most commonly infect the cornea
are bacteria (Staphylococcus aureus and Pseudomonas
aeruginosa), viruses (Herpes simplex and Herpes zoster), and fungi (Fusarium, Aspergillus, and Candida).
Bacterial keratitis. Bacterial keratitis is the most common form of infectious keratitis and is more frequent
in contact lens wearers. In both C57BL6 and BALB/c
mouse strains, infection results in rapid recruitment of
neutrophils which activate cytotoxic T cells and macrophages.59 C57BL6 mice mount a Th1 immune response
to bacterial infection whereas BALB/c mice mount a
Th2 response.69,70 The Th1 response is pro-inflammatory; Th1 mice clear bacteria more quickly than Th2
mice but, in doing so, the immune response causes
more corneal damage. Thus, the immune response in
the Th2 mice is anti-inflammatory when compared to
that seen in Th1 mice. The World Health Organization
(WHO) has found that the world’s leading cause of corneal blindness results from trachoma,71 a bacterial
infection endemic to developing countries that causes
permanent corneal scarring. In a 2010 study, WHO
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estimated that corneal blindness from all causes,
including trachoma, accounted for 7% of the world’s
blind population making it the 3rd most common cause
of blindness.72 Since trachoma can be treated by antibiotics, it is the leading cause of preventable blindness in
the world. Corneal scars are the leading cause of corneal transplants in the US.
Viral keratitis. In viral keratitis resulting from Herpes
simplex virus (HSV) infection, the virus infects the corneal epithelial cells and the intraepithelial corneal nerves
(ICNs). Retrograde transport in the ICN axons delivers
the virus to the trigeminal ganglion (TG) where the
nerve cell bodies are located.73-75 Acute HSV infection
attracts and activates dendritic cells, neutrophils, monocytes, and macrophages leading to a so called “cytokine
storm” at the TG and the ocular surface.75-77 Within
3 days, Natural killer (NK) T cells that specialize in
eliminating viruses begin accumulating in the cornea.78,79 In mice, between 6 and 8 days after acute infection, the virus enters a latent state within trigeminal
neurons and causes no symptoms. Herpes stromal keratitis (HSK) results from reactivation of latent HSV. Cytotoxic T cells are key to the immune response in HSK79;
viral reactivation also induces neutrophil accumulation
within the trigeminal ganglion. If HSK is not controlled,
viral particles replicating in the TG can travel to the
brainstem and cause lethal encephalitis. HSK causes
corneal fibrosis and focal loss of sensory innervation to
the cornea due to death of TG neurons.80 Neurotrophic
keratitis due to a complete loss of sensory innervation
will result from repeated bouts of HSK reactivation.81
Herpes Zoster infections are less frequent and believed
to be controlled by the cornea’s immune system similarly to HSV.82
Fungal Keratitis. Fungal keratitis has historically been
associated with trauma to the cornea that involves
plant matter and/or objects contaminated with soil. In
the United States, Candida and Aspergillus are the
most common causes; however, in South Florida,
Fusarium is more common. Diagnosis is often made
only after a corneal ulcer develops with fungi penetrating far into the corneal stroma. The immune
response of the cornea to a fungal infection is
robust83; the damage done to the tissue by immune
cell recruitment is significant.84,85 Modulating the
immune response has become a major target of
research efforts to reduce the damage seen in corneas
with fungal keratitis. IL6 is one of several cytokines
increased after fungal infection of the cornea; IL6
plays roles in macrophage activation and T cell differentiation. In a mouse model of fungal keratitis,85 mice
treated with a neutralizing antibody against IL6 had
fewer immune cells infiltrating the cornea and in the
draining lymph nodes. Additional studies are
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underway that may result in new treatments to reduce
the damage done to the cornea by fungal keratitis.

GLAUCOMA: AN EYE DISEASE INVOLVING
INFLAMMATION AND FIBROSIS IN BOTH THE
ANTERIOR AND POSTERIOR CHAMBERS OF THE EYE

Glaucoma encompasses a number of age-related
degenerative eye diseases, the most common form
being open-angle glaucoma (OAG), with other types
including angle-closure glaucoma and uveitic glaucoma.86,87 Glaucoma is defined as an optic neuropathy,
most typically associated with high intraocular pressure
(IOP) resulting from a block of aqueous humor outflow
from the anterior chamber of the eye.86,87 In both
open-angle and closed-angle glaucoma, inflammatory
cytokines are elevated in the aqueous humor.88-91 However, the biggest threat to vision from this increased
IOP is the death of retinal ganglion cells (RGCs),
whose axons exit the retina through the optic disc
where they are bundled together to form the optic
nerve. As a result of RGC death, glaucoma patients
experience loss of vision, beginning with their peripheral vision. Without treatment, glaucoma will lead to
blindness.87 Most therapeutic approaches are aimed at
lowering pressure by increasing aqueous humor outflow using either topical pharmaceuticals, or surgical
approaches including laser treatments as well as more
invasive surgical techniques.92 Glaucoma drugs that
increase fluid drainage from the eye include the commonly used prostaglandin analogs, Rho kinase inhibitors, nitric oxides, and miotic or cholinergic agents.93
Another pharmaceutical approach is to lower the
amount of fluid made by the eye. Examples of the
drugs that target fluid production include alpha-adrenergic agonists, beta blockers, and carbonic anhydrase
inhibitors.93 While a machine learning approach has
been able to accurately predict glaucoma based on the
profile of immune mediators in the aqueous humor,94
no current drug treatments of OAG are targeted at suppressing inflammation in the anterior or posterior
chambers, and some therapeutics including the prostaglandin analogs have the potential to induce an inflammatory response. Glaucoma filtration surgery can be
highly effective at lowering IOP.95 The primary reason
that this approach fails is scarring at the incision site in
the region of the conjunctiva/Tenon’s capsule. An
interesting new approach being investigated to prevent
scarring at this site involves a clinically relevant biomimetic of this subconjunctival tissue that includes an
immune component.96 Importantly, as the primary goal
of all glaucoma therapies is to prevent damage to the
retina and the optic nerve, there is much focus on
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developing effective neurotherapeutics for glaucoma
that would prevent RGC death.97-100 When such neuroprotective treatments are widely available, the outcomes of glaucoma will be greatly improved.
The aqueous humor is a nutrient source for several
avascular regions in the anterior segment including the
cornea, lens and trabecular meshwork (TM).101 It is
produced by the ciliary epithelial cells that line the ciliary body and occupies the space between the cornea
and the iris/lens. Normal pressure is maintained in the
eye by outflow of the aqueous humor through the TM,
a spongy tissue at the intersection of the posterior cornea and the iris consisting of stromal cells, fibroblasts
and immune cells within a loose connective tissue.102
From the TM, the drainage pathway leads to
Schlemm’s canal, a blind-ended vessel with lymphatic
properties that transports aqueous humor and antigen
presenting cells (APCs)103-105 into episcleral veins via
the aqueous veins.106
Outflow blockage in glaucoma correlates with an
increase in the stiffness of the TM and the lymphatic
endothelial cells that line Schlemm’s canal. These features have been linked to changes in the biomechanics
of the constituent cells,107 and the activation of profibrogenic pathways.108 In open angle glaucoma, stiffness of the TM is also associated with increased deposition of matricellular proteins including tenascin-C
and thrombospondin,109 both associated with woundrepair and fibrosis. The alterations to the matrix microenvironment in glaucoma are accompanied by changes
to the cytoskeleton of TM stromal cells that contribute
to a fibrotic outcome.110,111 The increased stiffness of
Schlemm’s canal in glaucoma is also linked to
increased presence of actin stress fibers as well as
assembly of vinculin-rich focal adhesions in its endothelial cells.107
The stiffening of the TM is a feature shared among
most types of glaucoma and is linked to the induction
of both TGF b /SMAD111-114 and Rho/Rock signaling
pathways,115,116 the increased production of matricellular proteins,109 and fibrosis117. Resident stromal cells,
fibrocytes (mesenchymal cells that form from monocyte precursors118), and other mesenchymal cell populations are all potential myofibroblast progenitors in
the TM, and contributors to fibrosis. In other tissues,
the appearance of myofibroblasts and the production
of a pro-fibrogenic microenvironment is often linked
to an inflammatory response.119-121 It will be important to establish whether there is a direct link
between inflammation, fibrosis, and the stiffening of
the trabecular meshwork associated with the onset
of open angle glaucoma with evidence-based studies. However, the likelihood of a significant immune
component in glaucoma, including as a potential
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cause of the stiffness of the trabecular meshwork,
can be drawn from studies showing the presence of
proinflammatory molecules in the aqueous humor
proteome of patients with POAG.91,122 Studies of
uveitic glaucoma, a rarer form of the disease, provide more direct evidence of a causative link
between immune cells and the induction of glaucoma in the anterior chamber.123 Uveitis is inflammation of the middle layer of the eye, the uvea,
which functions to provide the vascular support
required for phototransduction. As seen in other
types of glaucoma, this inflammatory condition
causes glaucoma by blocking aqueous humor outflow through the trabecular meshwork.124 Inflammation and fibrosis are also outcomes of the repair
response to surgical treatments for glaucoma.125
In contrast to the limited evidence regarding the
causative role of inflammation in stiffening of the trabecular meshwork, the damaging effects of glaucoma
on the retina and optic nerve are closely tied to inflammatory responses. Neuroinflammation, defined as
inflammation of nervous tissue, is considered a major
factor in the death of RGCs and their axons in the optic
nerve.126,127 The features associated with neuroinflammation in glaucoma are typical of classical neurodegenerative pathologies.128 Muller glia, astrocytes, and
microglia are resident to the retina and astrocytes are
present at the optic nerve head. These glial cells have
innate immune-like functions, performing immune surveillance and functioning as rapid responders to retina
damage or injury.126 Both astrocytes and Muller glia
cells are activated in glaucoma and linked to its pathogenesis.129,130 Following RGC cell death as a result of
elevated IOP, the pro-inflammatory pathways that activate astrocytes and microglia are likely to be induced
by DAMPs (damage-associated molecular patterns)
released by damaged RGC cells.131 This pathway has
been proposed to mediate early stages of glaucoma.
Following their migration to sites of injury in the retina, these activated astrocytes have the potential of
forming glial scars.132,133
The microglia in the retina, like all CNS microglia,
express antigens common to macrophages and monocytes,134 and are the progeny of monocytes that populate the retina during development. Importantly, in
addition to astrocytes and microglia, the neuroinflammatory response in glaucoma also involves bloodderived immune cells, including circulating monocytes.126 In fact, the infiltration of proinflammatory
monocytes into the retina and optic nerve head has
been linked to the onset of glaucoma in animal models of the disease.126,135 Gene ontology analytics have
shown that genes associated with the immune
response, including leukocyte activation and
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chemotaxis, are among the earliest genes upregulated
in the DBA/2J mouse model of glaucoma.126 These
genes are induced at a time when IOP is elevated, but
prior to a detectable loss of axons, suggesting that
these immune cells may have a causative role in the
retinal damage that occurs in glaucoma.
There is additional evidence that the impact of glaucoma on RGCs may involve inflammatory responses
early in the disease process.126 Studies with DBA/2J.
Wlds mice suggest that early immune responses in glaucoma are linked directly to high IOP and are independent of RGC dysfunction.136 Progressive degeneration
of RGCs and axons associated with neuroinflammation
also occurs in patients with a normal IOP (normal tension glaucoma),137 suggesting yet another mechanism
that can lead to inflammation and retinal damage in
glaucoma. Importantly, the risk of both glaucoma and
neuroinflammation increases with age.
In experimental models of glaucoma, the activated
glial cells of the retina express MHC-II proteins and
produce proinflammatory cytokines and chemokines
including TNF a .138,139 The expression of these molecules is associated with infiltration by blood-derived
immune cells.140,141 In addition to activation of microglia, acute elevation of IOP induces accumulation of
hyalocytes from the vitreous and macrophages into the
subretinal space.142 These immune cells provide
another source of pro-inflammatory cytokines .143 In
human glaucoma, proinflammatory cytokines, particularly TNF a, are increased in the vitreous, retina and
optic nerve.127,144-147
As research continues to advance our understanding
of the immune response and its regulation, it has
become clear that immune privileged sites like the eye
possess immune competence.148 In addition, in degenerative eye diseases of the retina, it has been shown
that the blood-retinal barrier is compromised.149 Evidence that this occurs in glaucoma include the detection of autoantibodies in the retina150 and the
infiltration by inflammatory leukocytes and macrophages139 that have been detected even before glaucoma symptoms are evident.151 There is both clinical
and experimental evidence that neurodegeneration
occurring as a result of high IOP in glaucoma is associated with a Heat Shock Protein (HSP)-dependent T cell
response.152,153 And the protection from glaucomatous
RGC loss provided in Rag1-/- (T- and B-cell-deficient)
knockout mice in which IOP elevation has been
induced provides further evidence of a role for the
immune response in glaucoma.154 In a mouse model of
glaucoma, neuronal damage is minimized or prevented
when monocyte entry into the optic nerve head is
blocked pharmacologically, genetically, or through
radiation treatments.135,155,156
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PROTECTIVE AND REPARATIVE IMMUNE RESPONSES
TO WOUNDING IN THE LENS AND THEIR LINKS TO
FIBROSIS

The lens is suspended in the center of the eye by tendon-like ciliary zonule fibers. These zonules link the
lens to the ciliary body, which is located behind the iris
and in front of the retina along the periphery of the eye.
The zonules are made of fibrillin that is produced by
the nonpigmented ciliary epithelial cells.157 Accommodation, the process by which lens shape is constantly
altered to focus images on the retina,158,159 is transmitted through the ciliary zonules and regulated by contraction of the smooth muscle cells of the ciliary body.
Together, the lens and ciliary zonules define a border
between the aqueous humor in the anterior chamber of
the eye, and the vitreous humor in the posterior eye
chamber, both of which are in direct contact with the
superficial surface of the matrix capsule that surrounds
the lens.
While the ciliary body has a rich vasculature, the
adult lens is a transparent, avascular tissue. A vasculature is associated with the embryonic lens during its
development in mammalian (not avian) species that is
removed around the time of birth. The fact that the eye
is considered an immune privileged site, and that the
lens is avascular160 and surrounded by a thick matrix
capsule,161 had led investigators to presume that
immune cells would not be associated with or recruited
to wounded or dysgenic lenses, even though noncanonical mechanisms of immune cell recruitment had
been discovered for other avascular regions of the
eye.65,162 It is only recently that it has been shown that
there is surveillance of the lens by immune cells in
response to eye injury, an adaptive immune response to
lens degeneration, and a repair response by immune
cells activated upon lens wounding.163-165 These studies also provided evidence that the association of
immune cells with the lens has negative outcomes,
including a role for immune cells in lens fibrosis.164,165
As a relatively new area of study, there still remains
much to learn about the innate and adaptive immune
responses to lens wounding, the mechanisms regulating
surveillance of the lens by immune cells, and how
inflammation can lead to impairment of lens function.
Here we review the significant progress that has been
made in the early stages of investigating lens immune
responses to wounding.
Evidence of an adaptive immune response to lens

One of the earliest pieces of evidence
that the lens has the ability to mount an adaptive
immune response came from studies with an N-cadherin lens-conditional knockout (N-cadDlens) mouse.164
The absence of N-cadherin causes a progressive
degeneration.
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degeneration in the region of the lens occupied by the
lens fiber cells.166 The morphogenetic defects and subsequent apoptotic death of these lens fiber cells leads to
the recruitment of macrophages followed by B and T
cells, in the presence of an intact lens capsule.164 The
immune cells recruited to these dysgenic lenses are
induced to express the myofibroblast protein aSMA
prior to the development of cataract-like opacities in
adult N-cadDlens mice.164 The appearance of myofibroblasts was correlated with the presence of a collagen Irich matrix in the dysgenic regions of these lenses, a
microenvironment that has been associated with various lens cataract phenotypes.
Lens resident immune cells. Consistent with the discovery that immune cells are recruited to regions of
lens degeneration, the normal lens was found to harbor
a population of resident immune cells.165 While not
previously described in the lens, resident immune cells
have been characterized in almost all tissues,167,168
including other immune privileged sites in the body
such as the cornea and the hair follicles of the
skin.169,170 Resident immune cells are activated upon
injury to function as the earliest responders to a wound
site and have been called sentinels of the immune system. They play essential roles in maintaining tissue
homeostasis including functions in guarding against
infection, clearing cellular debris, and immune surveillance.168 Resident immune cells also have an active
role in directing wound closure, an innate immune
response that has evolved over time. While resident
macrophages with a hemangioblastic lineage had been
identified amongst the cells of the lens primordium,171,172 it was initially believed that they disappeared early in lens development, following lens
vesicle closure.172 It is now known that a population of
lens resident immune cells is established during embryonic development and maintained in the adult.165 Analogous to resident immune cells in the cornea, the
resident immune cells of the lens are located interspersed between the cells that make up the lens epithelium in all species examined thus far, including
humans.165 They are activated upon cataract surgery
wounding to rapidly populate sites of lens epithelial
cell injury. Among them are immune cells with dendritic morphologies that express MHC type II antigen,
identifying them as antigen presenting cells (APCs).165
This finding suggests that lens APCs play a role in the
adaptive immune response activated in response to lens
dysgenesis.
Post-cataract surgery fibrosis

Posterior capsule

Cataract surgery removes the differentiated lens fiber cells that comprise the bulk of the
lens, leaving behind the matrix capsule surrounding the
lens and the closely associated wounded lens epithelial
opacification (PCO).
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cells amongst which the resident immune cells reside.
An intraocular lens is implanted within this capsular
bag that replaces the function of focusing images on
the retina. While generally a highly successful procedure, a large number of post-cataract surgery patients
develop a fibrotic vision-impairing condition called
posterior capsule opacification (PCO) along the fiber
cell-denuded region of posterior lens capsule.173 At the
cellular and molecular level, PCO is linked to the
appearance of Collagen I-producing, aSMA+ myofibroblasts, of which one well-characterized source is
the epithelial-mesenchymal transition (EMT) of lens
epithelial cells.174-188 The resident immune cells of the
lens also have been identified as a progenitor source of
aSMA+ myofibroblasts post-cataract surgery.165,189
These immune cells are highly susceptible to being signaled to transition to a myofibroblast phenotype, an
outcome promoted by factors in their microenvironment. In addition, the identification of a population of
resident APCs in the lens165 is consistent with their
recruitment of neutrophils and monocytes to the postcataract surgery lens. These immune cell types have
been demonstrated to convert to aSMA+ myofibroblasts that are associated with the development of fibrosis.119,121 A direct link between the inflammatory
response to cataract surgery and post-cataract surgery
fibrosis was shown in clinical studies which demonstrated that the use of anti-inflammatory steroid medications in cataract patients reduced PCO to levels that
did not require surgical treatment to restore vision.190
Cytokine and immune responses to cataract surgery.

Studies with a mouse cataract surgery model have
shown that circulating innate immune cells are
recruited to the lens post-wounding.191 The recruitment
of these immune cells to wounded lens tissue occurred
subsequent to the rapid induction of chemoattractant
and pro-inflammatory cytokines by the injured lens tissue.191 These studies demonstrated that the lens inflammatory response to wounding includes the induction of
pro-inflammatory proteins like S100a9 and chemoattractants for neutrophils, macrophages, and monocytes,
including the chemokines CXCL1, CCL2 (monocyte
chemoattractant protein-1 (MCP-1)). The induction of
each induced cytokine and chemokine was shown to
have a distinct profile for how quickly and how long it
was elevated post-cataract surgery.191. This mouse cataract surgery model also showed that cells expressing
aM integrin, a receptor expressed by both neutrophils
and macrophages, are among the earliest innate
immune cells to become associated with the post-surgery lens capsular bag, and were followed by immune
cells expressing F4/80, an antibody that identifies a
subset of macrophages.192 Interestingly, F4/80 is the
immune cell marker used to identify the presence of
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tissue resident macrophages within the lens primordium.172 The results of these post-cataract surgery
wounding studies also suggest a link between the
inflammatory response to lens wounding and the mechanisms responsible for TGF b -activation and the
induction of fibrosis.191
Surveillance of the Lens by Immune Cells in Response to

Immune surveillance protects tissues, with a
primary role in maintaining tissue homeostasis. This
phenomenon is best studied in cancer research in the
context of the activation of both innate and adaptive
immunity to eliminate cancer cells, as well as the
mechanisms used by cancer to evade surveillance by
immune cells.193. Interestingly, studies with the NcadDlens mouse revealed that lens degeneration activated an immune surveillance response in other regions
of the eye, including the central cornea and retina.164 In
a mouse model of optic nerve injury, it was discovered
that injuring the lens induced the secretion of factors
by macrophages that stimulated axon regeneration by
the injured retinal ganglion cells.194
Evidence of cooperative immune responses in the
eye was also provided by studies revealing that surveillance of the lens by immune cells is induced in
response to debridement wounding of the cornea.163 In
these studies, it was discovered that within one day of
cornea wounding, immune cells sourced in the ciliary
body are induced to travel along the ciliary zonules and
populate the lens anterior surface from where they
migrate across the lens capsule (Fig 3).163 While these
studies identified the ciliary body as a source of
immune cells that both surveille and become associated
with the lens, the hyalocytes located in the vitreous
Eye Injury.
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humor just posterior to the lens195 are also a potential
source of the immune cells that surveille the adult lens.
The finding that there is active surveillance of the lens
by immune cells that can migrate across the lens capsule to populate this avascular tissue suggests that the
high level of cataractogenesis in autoimmune diseases
such as diabetes and uveitis196,197 may be linked to the
high concentration of immune cells in the aqueous and
vitreous humors in these diseases. Similarly, since
anterior subcapsular cataracts (ASC) result from ocular
trauma, and this trauma also induces the accumulation
of cytokines and inflammatory cells in the aqueous
humor,198 it should be considered that the aSMA+
myofibroblasts and a collagen I-rich matrix that characterize ASC opacities may be linked to immune cells
that become associated with the lens.
The impact of uveitis on cataract surgery outcomes. Uveitis is a multifactorial inflammatory disease that has
destructive effects in both anterior and posterior segments of the eye.148,199-201 It is characterized by inflammation within the uvea, the middle layer of the eye that
contains most of its vasculature. The uvea is located
between the sclera and the retina, and includes the iris,
the ciliary body, and the choroid. While uveitis is linked
to diseases, injuries and/or infections of the eye, it can
also be a component of autoimmune or inflammatory
disorders that occur in other parts of the body, such as
sarcoidosis. The most common type of uveitis occurs in
the front of the eye, anterior uveitis, in the region
between the cornea and lens. Other forms of uveitis are
intermediate (occurring primarily in the vitreous), posterior (retina and choroid) and panuveitis. When
untreated, uveitis can lead to scarring, swelling or

Fig 3. Surveillance of the lens by immune cells in response to wounding of the cornea. (A) Model of immune
cells (green) traveling between the ciliary body (CB) and the lens along ciliary zonules (CZ, red) that link to the
equatorial (EQ) lens capsule and extend along the capsule surface under physiological conditions (left panel),
and migrating to the anterior surface of the lens to surveille this tissue in response to corneal debridement
wounding (right panel); (B) 3D surface structure rendering of a confocal Z-stack imaged at one day post-corneal
wounding showing immune cells (CD45+, green) migrating along within ciliary zonule (CZ) fibrils (MAGP1,
white) that extend along the surface of the matrix capsule that surrounds the lens (perlecan, red). Also seen are
the ciliary zonules (white) that link the lens to the ciliary body (CB). Nuclei in both the lens and ciliary body are
labeled blue. This figure is adapted from DeDreu et al., FASEB J. (2020) 34:9316.163 For interpretation of the
references to color in this figure legend, the reader is referred to the Web version of this article.
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detachment of the retina, optic nerve damage, glaucoma,
and lens cataract, all of which are associated with vision
loss. While this inflammatory disease has been linked to
cataract formation,202 the exact mechanism is not yet
known. In contrast, there is a significant literature showing post-cataract surgery complications in patients with
uveitis, particularly if inflammation is not controlled
prior to surgery. The complications of cataract surgery
in patients with uveitis include PCO, glaucoma, macular
edema, and retinal detachments,173,203-205 evidence that
many regions of the eye are impacted by ocular inflammation after cataract surgery. Together with the discovery that immune surveillance of the lens is induced
when the cornea is wounded163 and the surveillance of
the cornea and retina by immune cells in induced in
response to lens degeneration,164 these findings demonstrate that immune responses across the eye are highly
interactive.

INFLAMMATION AND FIBROSIS IN THE RETINA:
EPIRETINAL MEMBRANES (ERMS) AND PROLIFERATIVE
VITREORETINOPATHY (PVR)
Idiopathic and secondary epiretinal membranes. Fibrotic deposits on the inner retinal surface are often
described in the clinical literature using the word
“membrane”.206 When retinal surgeons remove the
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fibrotic tissue from the retina, it peels off as an intact
sheet. While not a membrane in the cell biological
sense of a lipid bilayer, these structures are consistent
with the dictionary definition of membrane which is “a
thin soft pliable sheet or layer especially of animal or
plant origin.” (https://www.merriam-webster.com/dic
tionary/membrane). The term epiretinal membrane
(ERM) describes the layer of cells and extracellular
matrix deposited onto the inner surface of the retina as
a result of aging and pathology (https://www.asrs.org/
patients/retinal-diseases/19/epiretinal-membranes).
Numerous different ways to classify and describe retinal membranes have been proposed, adopted, and
revised making the literature on this subject challenging.
Idiopathic ERMs (iERMs) are typically diagnosed by a
clinician looking at the patient’s fundus, the region that
they see when looking through the cornea and lens to
the back of the eye and that encompasses the retina,
optic disc, macula, and fovea. Patients may not have any
symptoms but clinicians looking at the fundus often see
wrinkles near the macula in what are called macular
puckers.206 ERMs can also form due to ocular pathology; these ERMs are referred to as secondary ERMs
(2ry ERMs). Pathologies that lead to 2ry ERMs include
proliferative diabetic retinopathy, central vein occlusion,
uveitis, proliferative vitreoretinopathy, retinal detachment, surgery, trauma, macular hole, and retinitis

Fig 4. Fibrotic changes seen in the aging retina. When chronic inflammation occurs in association with agerelated idiopathic epiretinal membranes (iERMs) and posterior vitreous detachment (PVD) retinal pathologies
involving fibrosis are promoted. ILL= inner limiting membrane, PVR= proliferative vitreoretinopathy, RRD=
Rhegmatogenous (rupture, tear) Retinal Detachment. For interpretation of the references to color in this figure
legend, the reader is referred to the Web version of this article.
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pigmentosa.207 2ry ERMs are more visually impairing
due to their size, cellularity, pigmentation, and vascularization. However, iERMs along with posterior vitreous
detachments (PVDs), which are described below, also
can lead to serious visual impairment due to the traction
they exert around the macula which can lead to formation of macular holes, inflammation, and retinal detachment (Fig 4).
The adhesion of the retina to the retinal pigment epithelial (RPE) cells is unique in that it does not involve
cell:cell or cell:substrate adhesion molecules. Instead,
their interaction depends on the close relationship
established in the interdigitation of the outer segments
of the retina’s rods and cones with the apical microvilli
extended from RPE cells.208 The tips of the rod outer
segments are ensheathed by RPE microvilli.209,210 The
intraocular pressure inside the large posterior chamber
between the lens and the retina provides the force that
stabilizes retinal:RPE adhesion. This chamber is filled
with the vitreous humor, a gel-like substance consisting
of water, collagens, glycoproteins, proteoglycans, as
well as a number of hyalocytes. Transcriptional profiling
has shown that hyalocytes are a unique innate immune
cell type similar to resident macrophages that express
genes for antigen processing and presentation.207 Type
II collagen makes up 60% 75% of the collagens in the
vitreous with the remaining collagens being types V, IX,
and XI.211 Hyaluronic acid (HA) makes up 96% of the
total glycosaminoglycans in the vitreous and associates
with type II collagen fibrils covalently and non-covalently.212 Because their sugars bind and organize water
molecules, this proteoglycan:collagen interaction results
in gel formation. Type II collagen allows the vitreous to
adhere to the lens capsule anteriorly and the Inner Limiting Membrane (ILM) posteriorly. The ILM is a basement membrane structure that mediates vitreoretinal
adhesion and plays an important role in pathological
traction on the retina.213
As the vitreous ages, it undergoes changes in its
composition which leads to its contraction and to a
condition called Posterior Vitreous Detachment
(PVD). The National Eye Institute (NEI) states that
detachment of the vitreous from the retina typically
occurs after the age of 50; by 80 years of age, most
people have undergone PVD in both eyes (https://
www.nei.nih.gov/learn-about-eye-health/eye-condi
tions-and-diseases/vitreous-detachment). PVD can
occur slowly over time or acutely with or without
symptoms. PVD symptoms are a sudden increase in
the number or sizes of floaters or an increase in spontaneous flashes of light.214 PVD can be confirmed clinically using optical coherence tomography. Although
the vitreous detaches from the ILM, it remains attached
to the lens. As it shrinks, the collagen fibers in the
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vitreous pull on the ILM. Because adhesion of the vitreous collagens to the ILM is stronger at some sites
than others, PVD is sometimes incomplete. The forces
exerted on the retina during progression of PVD can
lead to retinal tears and detachment.215 When this takes
place near or within the macula significant damage to
vision can result. Such damage to or traction on the retina from PVD can be detected by an ophthalmologist.
The vitreous shrinks with age due to reduction in its
proteoglycan content, which can be visualized by staining with cupromeronic blue, a dye that binds to the
sugar residues on proteoglycans.216,217 Chondroitin
sulfate side chains on type IX collagen, a proteoglycan,
are reduced or lost completely in the aging vitreous.
Deglycanation of proteoglycans renders their core proteins more susceptible to proteolysis. As proteoglycans
are deglycanated and degraded, water within the gel
diffuses into the posterior chamber in a process referred
to as vitreous liquefaction.216
The composition of the ILM resembles that of a typical basement membrane (BM), consisting of type IV
collagen, laminins, nidogen-1, and the heparan sulfate
proteoglycans (HSPGs) perlecan and collagen XVIII.213
The ILM is produced by the Muller glial cells.218 After
the first 2 years of life, retinal Muller cells decrease production of ILM proteins. Muller cells are less abundant
and change their morphology within the macular region
of the eye. The thickness of the ILM is thinner at the
foveola (center of the fovea) in human and primate eyes
(30- 40 nm) than outside the foveola (0.9 1.0 mm at the
parafovea)219. Where it is thinner, the retina is more susceptible to traction forces exerted by the vitreous during
PVD or by ERMs. The ILM, like several other basement
membranes in the body, thickens with age220; while the
exact cause for age related ILM thickening is not
known, the mechanical forces exerted on the Muller
cells by age-related contraction of the vitreous have
been hypothesized to increase Muller cell synthesis of
ECM contributing to development of age related ERMs
and to retinal pathology.
Damage to the ILM caused by incomplete detachment of the vitreous exposes the inner retina to fluid
which leads to the most common type of retinal detachment, referred to as a rhegmatogenous (secondary to a
rupture or tear) retinal detachment (RRD). RRDs can
spontaneously reattach but, unfortunately, they often
result in permanent loss of vision.221 After detachment,
fluid from the vitreous enters the hole created. Immune
cells are recruited to the site from both the vitreous and
the vasculature under the RPE cells which disrupts the
blood:retinal barrier. RPE and glial cells become activated, and together migrate onto the surface of the
ILM, proliferate, and differentiate into myofibroblasts
forming a 2ry ERM.
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A recent study by Coltrini and colleagues looked at
RNA isolated from the cells present in iERMs obtained
by “membrane peeling” from 56 patients.222 The
iERMs were staged clinically and assigned scores of A
or B, with a score of B given to iERMs that were
thicker and more easily visualized due to vascularization and pigmentation from de-differentiated RPE
cells. The authors surveyed the literature and selected
20 genes frequently associated with iERM, which fell
into 4 different categories (cell proliferation genes, biological markers, ECM proteins, and cytokines/chemokines). Quantitative (q)PCR on the isolated RNA
showed that progression of iERMs from stage A to B
was associated with increased RNA expression of
genes associated with fibrosis and cell proliferation
and, surprisingly, a reduction in expression of Muller
cell specific genes.
In diabetics, and when retinal holes and tears are large,
2ry ERMs grow into the posterior chamber, often along
fragments of partially detached vitreous. Patients with retinal membranes partially attached to the ILM and floating
within the vitreous are said to have Proliferative Diabetic
Retinopathy (PDR) or Proliferative Vitreoretinopathy
(PVR). PVR is defined as a pro-fibrotic syndrome that
occurs after any retinal tear, retinal detachment, or following the repair of a retinal detachment. Treatment for
iERMs, PDR, and PVR involves removing the vitreous
surgically (vitrectomy) along with the membranes and
the ILM.223 If a retinal detachment is also present, it will
be reattached using one of several different procedures.
Removing the vitreous eliminates tractional forces on the
retina and can allow retinal holes and tears to resolve.
Cataract surgery is often performed along with vitrectomy because removal of the vitreous from the posterior
aspect of the lens accelerates cataract progression.
Numerous different types of cells are present in
ERM membranes; the most abundant are those that
express aSMA and called myofibroblasts.224 Unlike
the myofibroblasts present in the trabecular meshwork
after glaucoma surgery and those present in the cornea
after trauma or refractive surgery, the myofibroblasts
in ERMs are often derived from cell types present only
in the retina including activated Muller glial and RPE
cells as well as immune cells recruited from the retinal
vasculature and from the vitreous.225 TGF b1 is known
to promote the growth of ERMs and PVR and is
expressed by several of these activated cell types.226,227
Researchers have attempted to identify factors that
could predict development of new ERMs and their
progression after vitrectomy.228 After RRD occurs,
ERMs develop in 4 stages: (1) ischemia and inflammation, (2) apoptosis, (3) cell proliferation, migration,
and myofibroblast formation, and (4) contraction of
membrane scars which leads to re-detachment of the
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retina These stages correlate only loosely to the 4
stages of ERM formation diagnosed clinically, which
are mild (A), moderate (B), marked (C1, C2, and C3),
and massive (D). The early ischemic phase initiates
when the ILM and retinal vessels break, and fluid separates the inner retina from the RPE cells. This
deprives the inner retina (photoreceptors, bipolar
cells, and retinal ganglion cells) of oxygen and
nutrients but does not induce ischemia in the outer retina and the RPE cells which continue to be perfused
by the choroidal vasculature.
Studies have shown that within 3 days of detachment, approximately 20% of photoreceptors die by a
combination of necrosis, apoptosis, and necroptosis.
By 28 days, more than 50% of the photoreceptors have
died. Cell death leads to release of angiogenic and
inflammatory growth factors that recruit more immune
cells from the choroidal vasculature. Following apoptosis of photoreceptors, the proliferation and differentiation of Muller glial and RPE cells into aSMA
expressing myofibroblasts occurs and extracellular
matrix accumulates forming membranes both on top of
the ILM and under the retina between the degenerating
photoreceptors and the RPE.226 Serum factors from
damaged and leaky blood vessels are also released into
the vitreous. Injecting peritoneal macrophages into the
vitreous of young rabbits induces ERM formation,
highlighting the critical role that immune cells play in
the development of ERMs.229 These macrophages
secrete FGF2 and TGF b1. T-helper cells are also
recruited. Their role is more complicated because they
can secrete both anti-inflammatory (IL10 and IFNg)
and proinflammatory (FGF2, PDGF, TGF b1, and
VEGF) cytokines and chemokines. Yet, mice lacking T
and B cells develop PVR in at similar rates in animal
models of the disease230 making it unlikely that PVR is
initiated by autoimmunity. Autoantibodies against type
II collagen do appear in the vitreous as PVR progresses
but are not thought to be causal.
A recent proteomic study aimed at understanding the
progression of PRV compared expression of 200 cytokines and chemokines in the vitreous of patients with
ERMs (the control group) to the vitreous of patients
with early (A, B) and advanced (C, D) stages of
PVR.231 There were more cytokines in the vitreous in
early PVR than late PVR. Pathway analysis shows that
the cytokines elevated in early PVR mediate T-cell
recruitment and mTOR signaling, while in late PVR
the predominant cytokines are involved in monocyte
responses and stem-cell recruitment. The authors conclude that early PVR membranes are dependent on Tcell mediated cell signaling. Based on this proteomic
data, several potential new therapeutics for treating
PVR in its early stages are suggested: mTOR inhibitors
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(sirolimus and metformin), the PI3K inhibitor (Idelalisib), and an IL13 inhibitor (Lebrikizumab).
Vitrectomy and membrane peeling remain treatments of choice for PVR to quickly release all tractional forces on the retina and to encourage tears to
repair themselves. Success rates for closing idiopathic
macular holes by vitrectomy in non-diabetics ranges
from 85% 100%.206 Large tears or holes are less
likely to completely resolve after surgery. Developing
therapeutics that could be administered at the time of
vitrectomy to stop or delay further progression of PVR
should be a goal to help preserve the remaining visual
acuity of these patients.

CONCLUSIONS

It is becoming increasingly evident that understanding immune responses in the avascular regions of the
eye holds the key to developing therapeutics that can
effectively protect the eye, promote repair and block
fibrotic outcomes that are particularly prevalent as the
eye ages. In this review, we highlight the cooperative
immune surveillance responses that are activated
when one region of the eye is injured or experiences
a degenerative pathology. While pathology in the posterior segment has long been known to accelerate cataract formation in the anterior segment, how it
impacts the rest of the anterior segment is underappreciated. Because of age-related PVD and vitreous liquification, cytokines induced by retinal pathology can
diffuse into the aqueous. There they can induce
recruitment of immune cells into the anterior segment
inducing and/or accelerating fibrosis and basement
membrane thickening in the cornea, lacrimal and Meibomian glands, and in the TM. Likewise, chronic
non-infectious keratitis and repeated reactivation of
viral keratitis induce immune cell activation, recruitment, and cytokine secretion into the aqueous.
Because of vitreous liquification, these cytokines diffuse into the vitreous where they activate hyalocytes
and accelerate the progression of age related ERM
formation, retinal traction, and progression to PVRs.
Since cells and tissues in both the anterior and posterior segments of the eye can cause fibrosis secondary
to inflammation, treatments to prevent fibrosis need to
consider their impact on the entire eye and not just
one region.
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